Updated findings on dual HER2 inhibition in HER2+ breast cancer
Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual...
Unit News from Breast Cancer
Researchers from the Clínic-IDIBAPS recognized with various grants at the SEOM congress
Five researchers from the Clínic-IDBAPS were recognized with various grants worth a total of €122,000 at the Spanish Society of Medical Oncology (S...
Researchers analyse the efficacy of immunotherapy combined with chemotherapy in the treatment of early breast cancer
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) comb...
The FERO Foundation and the Clínic-IDIBAPS join Forces for Cancer Research
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Program...
Dr. Aleix Prat receives one of the two Meta-prizes in the 4th Edition of the M. Chiara Giorgetti Award for research into metastatic breast cancer
These awards are organized by the Spanish Metastatic Breast Cancer Association to promote research in this area. The project presented by Dr. Alei...
Dr. Sònia Anglès Acedo: “Having positive sexual health results in a better quality of life”
Sexual health is an important part of anyone's life and has an impact on their overall health. Often, when a person is suffering from a disease, it...
HER2DX® recognized by TIME as one of the best inventions of 2022
HER2DX® was highlighted in Times 'Medical Care' category, which publicizes inventions that are successfully implemented in medical practice.
What is the difference between a mammogram and a breast ultrasound?
Both imaging techniques detect breast lesions, but have differences between them.
The Hospital Clínic starts an immunotherapy trial based on tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer
Trial TILs001, which is open to patients with metastatic triple-negative breast cancer, is the first study to assess the safety and efficacy of TIL...
A new treatment is effective for advanced HER2-low breast cancer
Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease an...